t
Aptamer Group plc published a Block Listing Interim Review for The Aptamer Group EMI Share Option Scheme. For the period from 25 August 2024 to 24 February 2025, no ordinary shares were issued under the scheme, while 1,090,424 ordinary shares lapsed or were waived. This leaves a balance of 576,053 ordinary shares not yet issued from the original admission of 2,063,200 ordinary shares on 25 February 2022.
| Date | 25 Feb 2025 |
| Time | 07:01:00 |
| Category | Capital structure |
| ID | 2691Y |
25 February 2025
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Block Listing Interim Review
Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, makes the following notification pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies regarding its existing block admission:
|
Name of Company |
Aptamer Group plc |
|
Name of Scheme |
The Aptamer Group EMI Share Option Scheme |
|
Period of Return (from/to) |
25 August 2024 to 24 February 2025 |
|
Number and class of securities not issued at the start of the period under the scheme |
1,666,477 Ordinary Shares |
|
Number of securities issued under the scheme during the period |
0 |
|
Number of securities lapsed/waived under the scheme during the period |
1,090,424 Ordinary Shares |
|
Balance under the scheme of securities not yet issued at the end of the period |
576,053 Ordinary Shares |
|
Number and class of securities originally admitted and the date of admission |
2,063,200 Ordinary Shares on 25 February 2022 |
|
Name of contact and telephone number |
Andrew Rapson +44 (0) 1904 217 404 |
- Ends -
For further information, please contact:
|
Aptamer Group plc Arron Tolley, Chief Executive Officer |
+44 (0) 1904 217 404 |
|
SPARK Advisory Partners Limited - Nominated Adviser Andrew Emmott / Jade Bayat |
+44 (0) 20 3368 3550 |
|
Turner Pope Investments (TPI) Limited - Broker James Pope / Andrew Thacker |
+44 (0) 20 3657 0050 |
|
Northstar Communications Limited - Investor Relations Sarah Hollins |
+44 (0) 113 730 3896 |
About Aptamer Group plc
Aptamer Group is a leading global developer of aptamer-based ligands that help scientists remove the limits to discovery and innovation. Leveraging several proprietary discovery and development platform, Aptamer delivers custom affinity ligands, supported with a complete suite of characterisation and validatory assays that enhance the translation of its binders and optimise scientific outcomes for customers.
Aptamer's cutting-edge technology spans healthcare, research, personal care, and industrial processes, delivering new affinity solutions for novel targets, advanced diagnostics, and precision therapies. By working with industry leaders in pharmaceutical, biotechnology, personal health, academic, and clinical research sectors, Aptamer is accelerating science through the custom development of tools and therapies.
To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/